Global drug makers face an extremely turbulent decade from which only highly innovative medicine makers and large-volume generics makers will emerge, with players who try to occupy the middle ground largely disappearing, the chief executive of Roche Holding AG (ROG.VX) said.
“We are in a perfect storm,” Severin Schwan told colleagues at pharmaceuticals conference.
